UK cost agency backs Celgene bone marrow drug in change of tack
LONDON (Reuters) - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - August 19, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint
US-based Amgen and its subsidiary, Onyx Pharmaceuticals, have reported data from the Phase III ASPIRE trial of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone to treat patients with relapsed multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 4, 2014 Category: Pharmaceuticals Source Type: news
Whistleblower Case Against Celgene Can Proceed, Says JudgeWhistleblower Case Against Celgene Can Proceed, Says Judge
A former employee alleges that Celgene engaged in unlawful marketing of thalidomide and lenalidomide and downplayed risks before the drugs were approved to treat cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Lenalidomide in Relapsed or Refractory Mantle Cell LymphomaLenalidomide in Relapsed or Refractory Mantle Cell Lymphoma
Get up-to-speed on studies of lenalidomide in relapsed/refractory MCL and compare the results with those of other novel agents being used for relapsed/refractory MCL. Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 21, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Chemotherapy-Free Combo Is Tested in CLLChemotherapy-Free Combo Is Tested in CLL
To avoid the toxicity of chemotherapy for chronic lymphocytic leukemia (CLL), standard rituximab treatment was combined with lenalidomide. The results disappointed an expert. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
CLL Drug Combo Boosts Survival (CME/CE)
MILAN (MedPage Today) -- Patients with relapsed/refractory chronic lymphocytic leukemia lived twice as long when treated with lenalidomide (Revlimid) plus an anti-CD20 antibody compared with lenalidomide alone, a series of clinical trials showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 19, 2014 Category: Hematology Source Type: news
Lenalidomide Plus R-CHOP Effective in Elderly DLBCL PatientsLenalidomide Plus R-CHOP Effective in Elderly DLBCL Patients
Adding lenalidomide to standard R-CHOP chemotherapy results in impressively high complete remission rates in elderly patients with diffuse large B-cell lymphoma (DLBCL). Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 30, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mylan Sues Celgene for Blocking Access to Generics
Generics giant Mylan is suing Celgene Corp, accusing Celgene of maintaining unlawful monopolies over Revlimid and Thalomid, by blocking generic versions from the market. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 8, 2014 Category: Pharmaceuticals Source Type: news
Clinical Trial for Newly Diagnosed Myeloma Patients
A clinical trial is enrolling newly diagnosed myeloma patients at over 100 medical centers in North America and Europe. This is a Phase 3 clinical trial in which the investigational oral drug MLN9708 is being studied in multiple myeloma to determine whether MLN9708 á taken in combination with lenalidomide and dexamethasone á may potentially slow the disease growth. Patients will have a 50 percent chance to receive either MLN9708 in combination with lenalidomide plus dexamethasone or a placebo in combination with lenalidomide plus dexamethasone. To learn more about this study and how to participate (Source: Intern...
Source: International Myeloma Foundation - March 21, 2014 Category: Hematology Source Type: news
OncoBriefs: Myeloma, Bone Markers, CT Scans
(MedPage Today) -- Patients with multiple myeloma had an increased risk of second hematologic malignancies when treated with the combination of lenalidomide and melphalan, authors of a meta-analysis concluded. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 14, 2014 Category: Gastroenterology Source Type: news
Lenalidomide and the Risk for Second Cancers in MyelomaLenalidomide and the Risk for Second Cancers in Myeloma
The combination of lenalidomide and melphalan significantly increases the risk for hematologic second malignancies and should be avoided. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 20, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Revlimid Slows Multiple Myeloma Relapse (CME/CE)
NEW ORLEANS (MedPage Today) -- For patients whose multiple myeloma is in remission after initial therapy, maintenance with the immune modulator lenalidomide (Revlimid) prolongs the time to relapse, a researcher said here. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 11, 2013 Category: Hematology Source Type: news
Lenalidomide Plus Dex Trumps Standard Tx in Multiple MyelomaLenalidomide Plus Dex Trumps Standard Tx in Multiple Myeloma
Combining lenalidomide with low-dose dexamethasone improved progression-free survival as first-line tx in multiple myeloma, compared with the standard melphalan, prednisone plus thalidomide. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ASH 2013 Preview: More Than 100 Interesting and Important Myeloma Abstracts
The IMF team reviewed the more than 800 ASH 2013 abstracts that were released last week and identified 131 myeloma abstracts worthy of specific comment. One of the top plenary session abstracts for ASH this year is the MM-020 study of Revlimid in newly diagnosed myeloma patients, says IMF Chairman Dr. Brian Durie. In the first of his two-part overview of the ASH 2013 abstracts, he focuses on those that looked at novel agents (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - November 17, 2013 Category: Hematology Source Type: news
Celgene raises 2013 forecast as profit beats estimates
(Reuters) - Celgene Corp raised its earnings forecast for 2013 on Thursday after reporting slightly higher-than-expected quarterly profit on robust sales of its flagship blood cancer drug Revlimid and rapid growth in newer cancer treatments. (Source: Reuters: Health)
Source: Reuters: Health - October 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
